Comment on: The male patient with obesity undergoing metabolic and bariatric surgery: changes in testosterone levels correlate with weight loss after one-anastomosis gastric bypass and Roux-en-Y gastric bypass.

Abstract

Male obesity-associated secondary hypogonadism (MOSH) is among a number of co-morbidities and health consequences associated with obesity [ [1] Carrageta D.F. Oliveira P.F. Alves M.G. Monteiro M.P. Obesity and male hypogonadism: tales of a vicious cycle. Obes Rev. 2019; 20: 1148-1158 PubMed Google Scholar ]. Although frequently neglected, this disorder has a relevant impact on patient quality of life and can affect life expectancy. Obesity has been identified as a primary cause of secondary hypogonadism and reproductive dysfunction. Adipose tissue aromatase can reduce testosterone levels by irreversibly converting testosterone to estradiol. Low testosterone levels may lead to alterations in body composition and promote abdominal fat accumulation while obesity, in turn, can further reduce testosterone levels. Additionally, high estradiol concentrations have been shown to mediate deleterious effects on male gonadal function. Thus, this bidirectional relationship of obesity-hypogonadism can easily become a vicious cycle. The male patient with obesity undergoing metabolic and bariatric surgery: changes in testosterone levels correlate with weight loss after one-anastomosis gastric bypass and Roux-en-Y gastric bypassSurgery for Obesity and Related DiseasesPreviewMale obesity secondary hypogonadism (MOSH) is a common disease among men with obesity and can be associated with metabolic syndrome and a variety of metabolic problems ultimately leading to androgen deficiency. Metabolic and bariatric surgery is a well-established treatment option associated with significant weight loss and reduction in metabolic co-morbidities. Full-Text PDF